Literature DB >> 10651778

Interleukin-5 enhances eosinophil adhesion to bronchial epithelial cells.

D Sanmugalingham1, E De Vries, R Gauntlett, F A Symon, P Bradding, A J Wardlaw.   

Abstract

BACKGROUND: Eosinophil-bronchial epithelial cell interactions are thought to be central to the pathogenesis of asthma, both in terms of the epithelium as a source of pro-inflammatory mediators and as a target for eosinophil-mediated damage. We have therefore investigated adhesion interactions between these two cell types.
OBJECTIVES: To determine the role of eosinophil and epithelial activation on eosinophil adhesion to bronchial epithelium and to characterize the adhesion receptors mediating eosinophil adhesion.
METHODS: Eosinophils were purified from human peripheral blood by immunomagnetic selection and adhesion to confluent cultures of the airway epithelial cell lines A549 and BEAS-2B was studied.
RESULTS: Stimulation of A549 cells with TNFalpha, IFNgamma or a combination of 50 ng/mL of TNFalpha, IFNgamma and IL-1 (cytomix) did not effect eosinophil binding despite an increase in ICAM-1 expression. Similarly stimulation of eosinophils with PAF or IL-5 had no effect on eosinophil binding to medium- or cytokine-treated A549 cells. In contrast stimulation of BEAS-2B cells with cytomix caused a significant increase in eosinophil adhesion. This was associated with an increase in expression of ICAM-1 and induced expression of VCAM-1. Treatment of eosinophils with Mn2+ and IL-5 but not eotaxin, RANTES or PAF also significantly enhanced eosinophil adhesion to medium-treated BEAS-2B cells. Using blocking mAbs we were able to demonstrate that the increased adhesion resulting from stimulation of eosinophils or BEAS-2B cells was in both cases mediated by a combination of CD18 and alpha4 integrins.
CONCLUSIONS: This study demonstrates a selective role for IL-5 in mediating integrin-dependent eosinophil adhesion to airway epithelium and once again emphasizes the importance of this cytokine in controlling eosinophil activation in diseases such as asthma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651778     DOI: 10.1046/j.1365-2222.2000.00739.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  7 in total

1.  The effectiveness of fish oil supplementation in asthmatic rats is limited by an inefficient action on ASM function.

Authors:  D T S Z Miranda; A L Zanatta; B C L Dias; R T H Fogaça; J B B Maurer; L Donatti; P C Calder; A Nishiyama
Journal:  Lipids       Date:  2013-06-07       Impact factor: 1.880

2.  Distribution of major basic protein on human airway following in vitro eosinophil incubation.

Authors:  Ailing Xue; John Wang; Gary C Sieck; Mark E Wylam
Journal:  Mediators Inflamm       Date:  2010-03-22       Impact factor: 4.711

3.  Novel expression of vascular cell adhesion molecule-1 (CD106) by squamous epithelium in experimental acute graft-versus-host disease.

Authors:  Judith C Kim; Diana Whitaker-Menezes; Masatoshi Deguchi; Brigette S Adair; Robert Korngold; George F Murphy
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

4.  Clinical implications of CD4+ T cell subsets in adult atopic asthma patients.

Authors:  Matthew Wiest; Katherine Upchurch; Wenjie Yin; Jerome Ellis; Yaming Xue; Bobby Lanier; Mark Millard; HyeMee Joo; SangKon Oh
Journal:  Allergy Asthma Clin Immunol       Date:  2018-03-02       Impact factor: 3.406

Review 5.  Allergy and sports.

Authors:  S R Del Giacco; P E Manconi; G S Del Giacco
Journal:  Allergy       Date:  2001-03       Impact factor: 13.146

6.  Interferon-alpha inhibits airway eosinophilia and hyperresponsiveness in an animal asthma model [corrected].

Authors:  Yasuko Kikkawa; Kumiya Sugiyama; Kazuki Obara; Hirokuni Hirata; Yasutsugu Fukushima; Masao Toda; Takeshi Fukuda
Journal:  Asia Pac Allergy       Date:  2012-10-31

7.  Eosinophils in fungus-associated allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.